Arena Pharmaceuticals Stock News

Pharmaceutical giant Pfizer Inc. (NYSE:PFE) is entering the cannabis space via the $6.7 billion acquisition of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). The two publicly-traded companies confirmed

Arena Pharmaceuticals Inc (NASDAQ: ARNA) is soaring Monday morning after Pfizer Inc (NYSE: PFE) announced it would acquire the company for $100 per share. The all-cash transaction represents a tota

Analysts are on board with Pfizer Inc.'s PFE, +1.34% plans to acquire Arena Pharmaceuticals Inc. ARNA, -5.33% in a deal worth $6.7 billion and announced Monday morning. Pfizer's stock was up 1.2% in p

The stock price of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) increased by over 85% pre-market today. This is why it happened.

Pfizer agrees to buy U.S. biotech company Arena Pharmaceuticals in a deal valued at about $6.7 billion.

Pfizer Inc (NYSE: PFE) has agreed to acquire Arena Pharmaceuticals Inc (NASDAQ: ARNA), a clinical-stage company developing therapies to treat several immuno-inflammatory diseases.  Under the agre

Pfizer agrees to buy U.S. biotech company Arena Pharmaceuticals in a deal valued at about $6.7 billion, according to a regulator filing Monday.

(Reuters) -Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.

Pfizer Inc. PFE, +1.34% said Monday it has agreed to acquire Arena Pharmaceuticals Inc. ARNA, -5.33% in a deal with a value of about $6.7 billion. The news sent Arena shares up 91% in premarket tradin

Wells Fargo & Company assumed coverage on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a research note issued to investors on Wednesday morning, Analyst Ratings Network reports. The firm issued an overweight rating and a $71.00 price target on the biopharmaceutical companys stock. A number of other analysts have also commented on the company. HC Wainwright []

Bank of America Corp DE lowered its holdings in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 70.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,899 shares of the biopharmaceutical companys stock after selling 62,883 shares during the period. Bank of []

Equities research analysts predict that Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will announce ($2.41) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Arena Pharmaceuticals earnings, with estimates ranging from ($2.52) to ($2.32). Arena Pharmaceuticals posted earnings of ($2.10) per share in the same quarter last year, which indicates []

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has received an average recommendation of Buy from the twelve research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings []

SVB Leerink reaffirmed their buy rating on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a report issued on Wednesday morning, AnalystRatings.com reports. A number of other equities research analysts have also recently weighed in on the company. JMP Securities reaffirmed a buy rating and set a $105.00 price target on shares of Arena Pharmaceuticals in a []

Arena Pharmaceuticals (NASDAQ:ARNA)s stock had its buy rating restated by stock analysts at SVB Leerink in a report issued on Wednesday, AnalystRatings.com reports. ARNA has been the topic of several other research reports. Cantor Fitzgerald cut their price target on Arena Pharmaceuticals from $100.00 to $93.00 and set an overweight rating on the stock in []